Prescription medicine
Prednisolone and sulfacetamide First approved as Blephamide
Prednisolone and sulfacetamide (Blephamide) is a prescription medicine with an FDA approval on record since 1961. FDA's NDC Directory lists it from 2 generic labelers, and pharmacies paid $2.62 per mL (Sulf-pred 10-0.23% eye drops) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the prednisolone and sulfacetamide FDA label on DailyMed (effective August 1, 2023, Bausch & Lomb Incoporated); the NDA 12813 record on Drugs@FDA; every prednisolone and sulfacetamide label on DailyMed.
Highlights of the record
FDA label of August 1, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Forms and strengths
- 100 mg/ml / 2.3 mg/ml
Solution/ drops.
On the market
- Earliest approval on file
- September 18, 1961 Blephamide, Allergan; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 10 first July 21, 1981; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 2 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $2.62 per mL Sulf-pred 10-0.23% eye drops
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1 through July 30, 2026
What is prednisolone and sulfacetamide used for?
From the label: indications and usageSulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. […]
FDA pharmacologic class: Corticosteroid and Sulfonamide Antibacterial.
Source: FDA drug label (Sulfacetamide Sodium and Prednisolone Sodium Phosphate), Bausch & Lomb Incoporated, effective August 1, 2023 (SPL set 9ec403eb-b5df-4e41-9e17-9d9d8ecac3f3), via openFDA; the full label on DailyMed
Is there a generic for prednisolone and sulfacetamide (Blephamide)?
The FDA approved the first generic prednisolone and sulfacetamide on July 21, 1981. 10 generic applications are approved; 1 of them carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists prednisolone and sulfacetamide from 2 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1961 earliest approval on file
- 1981 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for prednisolone and sulfacetamide (Blephamide)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.62 per mL (Sulf-pred 10-0.23% eye drops), down 1% from $2.65 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Sulf-pred 10-0.23% eye drops (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Sulf-pred 10-0.23% eye drops | Generic | $2.62 per mL | n/a | -1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for prednisolone and sulfacetamide?
The FDA Adverse Event Reporting System holds 1 report that list prednisolone and sulfacetamide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other corticosteroids
- the pharmacologic class, with prices and generics
- Prednisolone and sulfacetamide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other